These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34743348)

  • 1. Pharmacokinetics and Safety of Intravenous Ferric Pyrophosphate Citrate: Equivalence to Administration via Dialysate.
    Marbury T; van Heuveln F; van der Horst E; Pratt RD
    J Clin Pharmacol; 2022 May; 62(5):681-688. PubMed ID: 34743348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis.
    Pratt RD; Grimberg S; Zaritsky JJ; Warady BA
    Pediatr Nephrol; 2018 Nov; 33(11):2151-2159. PubMed ID: 30003313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease.
    Gan L; Xie P; Tan Y; Wei G; Yuan X; Lu Z; Pratt R; Zhou Y; Hui AM; Li K; Fang Y; Zuo L
    Drugs R D; 2022 Jun; 22(2):119-129. PubMed ID: 35380419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients.
    Fishbane SN; Singh AK; Cournoyer SH; Jindal KK; Fanti P; Guss CD; Lin VH; Pratt RD; Gupta A
    Nephrol Dial Transplant; 2015 Dec; 30(12):2019-26. PubMed ID: 26175145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis.
    Zhang L; Gan L; Li K; Xie P; Tan Y; Wei G; Yuan X; Pratt R; Zhou Y; Hui AM; Fang Y; Zuo L; Zheng Q
    Eur J Clin Pharmacol; 2022 Sep; 78(9):1421-1434. PubMed ID: 35711066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferric pyrophosphate citrate for parenteral administration of maintenance iron: structure, mechanism of action, clinical efficacy and safety.
    Fishbane S; Ganz T; Pratt RD
    Curr Med Res Opin; 2022 Aug; 38(8):1417-1429. PubMed ID: 35726771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialysis.
    Shah HH; Hazzan AD; Fishbane S
    Semin Nephrol; 2016 Mar; 36(2):124-9. PubMed ID: 27236134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis.
    Fishbane S; Shah HH
    Hemodial Int; 2017 Jun; 21 Suppl 1():S104-S109. PubMed ID: 28371161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients.
    Gupta A; Lin V; Guss C; Pratt R; Ikizler TA; Besarab A
    Kidney Int; 2015 Nov; 88(5):1187-94. PubMed ID: 26154926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers.
    Pratt RD; Swinkels DW; Ikizler TA; Gupta A
    J Clin Pharmacol; 2017 Mar; 57(3):312-320. PubMed ID: 27557937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Options for Iron Supplementation in Maintenance Hemodialysis Patients.
    Vaziri ND; Kalantar-Zadeh K; Wish JB
    Am J Kidney Dis; 2016 Mar; 67(3):367-75. PubMed ID: 26616335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Institutional Usage of Ferric Pyrophosphate Citrate (FPC) Delivered Via Dialysate in Reducing Erythropoiesis Stimulating Agents (ESAs) and IV Iron Cost.
    Wang S; DellaFera L; Dhanani L; Malone B; Dutka P; Akerman M; Masani N
    Hosp Pharm; 2022 Jun; 57(3):355-358. PubMed ID: 35615489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis.
    Gupta A; Amin NB; Besarab A; Vogel SE; Divine GW; Yee J; Anandan JV
    Kidney Int; 1999 May; 55(5):1891-8. PubMed ID: 10231452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of Ferric Pyrophosphate Citrate (Triferic) Use in Hemodialysis Patients.
    Albright T; Al-Makki A; Kalakeche R; Shepler B
    Clin Ther; 2016 Oct; 38(10):2318-2323. PubMed ID: 27692637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ferric pyrophosphate citrate: interactions with transferrin.
    Pratt R; Handelman GJ; Edwards TE; Gupta A
    Biometals; 2018 Dec; 31(6):1081-1089. PubMed ID: 30311019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation.
    Scheiber-Mojdehkar B; Lutzky B; Schaufler R; Sturm B; Goldenberg H
    J Am Soc Nephrol; 2004 Jun; 15(6):1648-55. PubMed ID: 15153577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dialysate made from dry chemicals using citric acid increases dialysis dose.
    Ahmad S; Callan R; Cole JJ; Blagg CR
    Am J Kidney Dis; 2000 Mar; 35(3):493-9. PubMed ID: 10692276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
    Macdougall IC; Dahl NV; Bernard K; Li Z; Batycky A; Strauss WE
    BMC Nephrol; 2017 Apr; 18(1):117. PubMed ID: 28372549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physicochemical characterization of ferric pyrophosphate citrate.
    Gupta A; Pratt R; Mishra B
    Biometals; 2018 Dec; 31(6):1091-1099. PubMed ID: 30324285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients.
    Janssen MJ; Deegens JK; Kapinga TH; Beukhof JR; Huijgens PC; van Loenen AC; van der Meulen J
    Kidney Int; 1996 Mar; 49(3):806-13. PubMed ID: 8648924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.